Biohaven Pharmaceutical Holding Company Ltd.
http://biohavenpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biohaven Pharmaceutical Holding Company Ltd.
Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky
Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.
Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Biohaven Pharmaceuticals, Inc.
- Biohaven Therapeutics Ltd.
- BioShin
- Kleo Pharmaceuticals Inc.
- Portage Biotech Inc.
- Portage Glasgow Limited (PGL)